MyMD Pharmaceuticals, Inc.® (NASDAQ:MYMD) ("MyMD" or the "Company"), a clinical stage pharmaceutical company committed to developing novel therapies for age-related diseases, autoimmune and inflammatory conditions, announced statistically significant positive topline Phase 2 results for its next generation Oral TNF-α inhibitor MYMD-1 in Sarcopenia/Age-Related Frailty earlier this week. In conjunction with its release, the company also announced it will hold a conference call today, August 2nd, at 4:30pm ET to discuss the results. To participate in the conference call, please register here. A webcast can also be accessed under the ‘Events & Presentations' section on the Investors page at w

- MYMD-1 significantly reduced serum levels of chronic inflammatory markers and met all primary pharmacokinetic and secondary safety and tolerability endpoints across multiple doses over 28 days of treatment - MYMD-1 demonstrated statistical significance across three biomarkers: TNF-α (P=0.008), sTNFR1 (P=0.02), and IL-6 (P=0.03) - First Oral TNF-α inhibitor, if approved, would offer potential patient benefit in large markets - Company to present the data to FDA and intends to advance the clinical program for MYMD-1; will hold conference call on August 2, 2023, at 4:30 PM Eastern Time MyMD Pharmaceuticals, Inc.® (NASDAQ:MYMD) ("MyMD" or the "Company"), a clinical stage pharmaceutica

New name and stock symbol represents therapeutic focus on inhibiting TNF-alpha to regulate the immuno-metabolic system TNF Pharmaceuticals, Inc. (NASDAQ:TNFA) (formerly MyMD Pharmaceuticals, Inc.) (the "Company"), a clinical stage biopharmaceutical company committed to developing novel therapies for age-related diseases and autoimmune and inflammatory conditions, today announced that its common stock, listed on the Nasdaq Capital Market, begins trading under the new ticker symbol, "TNFA," effective before the market open today, July 24, 2024. The new trading symbol "TNFA" replaces the Company's previous trading symbol "MYMD" and coincides with the Company's previously announced corporat

New name represents therapeutic focus on inhibiting TNF-alpha to regulate the immuno-metabolic system Company plans mid-stage clinical trials of TNF-alpha inhibitor drug MYMD-1® following statistically significant Phase 2 studies TNF Pharmaceuticals will begin trading on Nasdaq under the new trading symbol "TNFA" effective July 24, 2024 TNF Pharmaceuticals, Inc., formerly MyMD Pharmaceuticals, Inc. (NASDAQ:MYMD) (the "Company"), a clinical stage biopharmaceutical company committed to developing novel therapies for age-related diseases and autoimmune and inflammatory conditions, today announced a rebranding to the new name "TNF Pharmaceuticals, Inc.," effective today. The Company's com

Dr. Glass brings a 35-year career in life sciences with multiple drug approvals including Accolate ®, Avandia ® and Coreg® Dr. Glass brings broad expertise in regulatory strategies: 5 NDAs and MAAs, 7 pre-NDA meetings, 12 End of Phase 2 meetings, and more than 80 INDs Company announces President and CMO transition as clinical development advances through mid-stage trials Company also appoints new independent board member, Mr. Stephen Friscia, an experienced investment strategist MyMD Pharmaceuticals, Inc. (NASDAQ:MYMD) ("MyMD" or the "Company"), a clinical stage biopharmaceutical company committed to developing novel therapies for age-related diseases and autoimmune and inflamm

Second external investment in life sciences solidifies previously announced strategy to utilize significant cash position to create additional stockholder value PharmaCyte Biotech, Inc. (NASDAQ:PMCB) ("PharmaCyte" or the "Company"), today announced a $7 million investment in MyMD Pharmaceuticals, Inc. (NASDAQ:MYMD) ("MyMD") a clinical stage biopharmaceutical company committed to developing novel therapies for age-related diseases, autoimmune and inflammatory conditions. MyMD has announced positive data for a 40-patient Phase 2 clinical trial for its lead product, MYMD-1 in sarcopenia, and is moving its clinical program forward in consultation with the U.S. Food and Drug Administration (FD

Up to $42 Million in Two-Part Funding from New Strategic Investor and Existing Shareholders with Committed Closing of an Aggregate of $14 Million Up Front MyMD Pharmaceuticals, Inc.® (NASDAQ:MYMD) ("MyMD" or "the Company"), a clinical stage biopharmaceutical company committed to developing novel therapies for age-related diseases, and autoimmune and inflammatory conditions, today announced that it has secured $7 million in commitments in two private placement funding rounds led by a strategic investor, PharmaCyte Biotech, Inc. (NASDAQ:PMCB), a clinical-stage biotechnology company developing cellular therapies for cancer and diabetes. An additional $7 million was raised from existing MyMD

MyMD Pharmaceuticals, Inc.® (NASDAQ:MYMD) ("MyMD" or "the Company"), a clinical stage biopharmaceutical company committed to developing novel therapies for age-related diseases, autoimmune and inflammatory conditions, today announced that it received notice from The Nasdaq Stock Market LLC ("Nasdaq") on March 4, 2024 informing the Company that it has regained compliance with the minimum bid price requirement under Nasdaq Listing Rule 5550(a)(2) ("Listing Rule") for continued listing on the Nasdaq Capital Market. On October 11, 2023, MyMD received notice from the Listing Qualifications Department of Nasdaq indicating that the Company was not in compliance with the Listing Rule, as its comm

Common Stock Will Begin Trading on Split-Adjusted Basis on February 15, 2024 MyMD Pharmaceuticals, Inc.® (NASDAQ:MYMD) ("MyMD" or "the Company"), a clinical stage biopharmaceutical company committed to developing novel therapies for age-related diseases, autoimmune and inflammatory conditions, announced today that it intends to effect a reverse stock split of its common stock at a ratio of 1 post-split share for every 30 pre-split shares. The reverse stock split will become effective at 4:05 p.m. Eastern Standard Time on Wednesday, February 14, 2024. MyMD's common stock will continue to be traded on the Nasdaq Capital Market under the symbol MYMD and will begin trading on a split-adjusted

BALTIMORE, MD / ACCESSWIRE / December 29, 2023 / A condition that commonly affects elderly populations, sarcopenia results in the gradual loss of strength and physical function and has become an important healthcare issue worldwide in recent years. A sarcopenia diagnosis comes with a greater risk of hospitalization, disability and death. With no FDA-approved medications for sarcopenia currently on the market, there is a need for treatments that can help patients live with this disease. In Europe and the USA, the prevalence of sarcopenia with different diagnostic criteria ranges from 4.6% to 43% in communities and from 23% to 68% in clinical settings, and a high prevalence of sarcopenia can c

Company targets first quarter 2024 for trial initiation Potential to be first orally-administered TNF-α inhibitor treatment for RA MyMD Pharmaceuticals, Inc.® (NASDAQ:MYMD) ("MyMD" or "the Company"), a clinical stage biopharmaceutical company committed to developing novel therapies for age-related diseases, autoimmune and inflammatory conditions, announced today that its Investigational New Drug (IND) application for a Phase 2 clinical trial of oral MYMD-1® as a treatment for rheumatoid arthritis (RA) was recently cleared by the U.S. Food and Drug Administration (FDA), and plans are underway for trial launch in the first quarter of 2024. "With the FDA's recent clearance of our IND in

- Supera-CBD eased heat-related pain due to inflammation quickly and provided long-lasting pain relief lasting up to five hours - Results suggest Supera-CBD may target specific pain pathways, lessening the potential for side effects - MyMD was issued Japanese Patent No. 7293561 B2, covering Supera-CBD as a new molecular entity, in pharmaceutical formulations, and for use in therapeutic treatments MyMD Pharmaceuticals, Inc.® (NASDAQ:MYMD) ("MyMD" or "the Company"), a clinical stage biopharmaceutical company developing groundbreaking therapies for the treatment of serious and debilitating autoimmune and inflammatory diseases, today announced results from a preclinical study of its inves

SC 13D - MyMD Pharmaceuticals, Inc. (0001321834) (Subject)

SC 13G - MyMD Pharmaceuticals, Inc. (0001321834) (Subject)

SC 13G/A - MyMD Pharmaceuticals, Inc. (0001321834) (Subject)

SC 13G/A - MyMD Pharmaceuticals, Inc. (0001321834) (Subject)

SC 13D - MyMD Pharmaceuticals, Inc. (0001321834) (Subject)

SC 13G/A - MyMD Pharmaceuticals, Inc. (0001321834) (Subject)

SC 13G/A - MyMD Pharmaceuticals, Inc. (0001321834) (Subject)

SC 13G/A - MyMD Pharmaceuticals, Inc. (0001321834) (Subject)

Dr. Glass brings a 35-year career in life sciences with multiple drug approvals including Accolate ®, Avandia ® and Coreg® Dr. Glass brings broad expertise in regulatory strategies: 5 NDAs and MAAs, 7 pre-NDA meetings, 12 End of Phase 2 meetings, and more than 80 INDs Company announces President and CMO transition as clinical development advances through mid-stage trials Company also appoints new independent board member, Mr. Stephen Friscia, an experienced investment strategist MyMD Pharmaceuticals, Inc. (NASDAQ:MYMD) ("MyMD" or the "Company"), a clinical stage biopharmaceutical company committed to developing novel therapies for age-related diseases and autoimmune and inflamm

MyMD Pharmaceuticals, Inc. (NASDAQ:MYMD), a clinical stage pharmaceutical company committed to extending healthy lifespan by focusing on developing two therapeutic platforms, announced today that it has appointed David Rini to the Company's Scientific Advisory Board. "I am delighted to join the MyMD Scientific Advisory Board and look forward to working on the development and communication about our two platforms," stated David Rini. David Rini is a Professor at the Johns Hopkins University School of Medicine in the Department of Art of Applied to Medicine, Cellular and Molecular Medicine, and Director of the Medical and Biological Illustration Graduate Program. Professor Rini earned his M